MAP2K7 and Miyoshi myopathy: Although blocking the RAS-RAF-MEK-ERK pathway was thought to be an attractive option for treating MM [6], the effects of inhibitors targeting the RAS-RAF-MEK-ERK pathway so far have been limited [6, 28], and new-generation RAS inhibitors are awaited.